Central vascular structures as a characteristic finding of regenerative nodules using hepatobiliary phase gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced MRI and arterial dominant phase contrast-enhanced US
Kazuya Sugimori(National Cancer Center Hospital East), Katsuaki Tanaka(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Masahiro Okada, Hiromi Nihonmatsu(Yokohama City University Medical Center), Masayuki Nakano(Nihon University), Shigeo Takebayashi(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital)
Cited by 21
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573